Indirect Treatment Comparison in Meta-Analysis Using Three Methods for Rheumatoid Arthritis

Authors

  • M. Iswarya

DOI:

https://doi.org/10.37591/rrjocb.v7i1.254

Abstract

Background: The data were extracted from the comparative effectiveness review (CER) on pharmacological treatments for rheumatoid arthritis (RA) developed by the International University of North Carolina Evidence Based Practice Center (UNC EPC). The included studies enrolled patients with active RA despite oral disease-modifying antirheumatic drugs (DMARD) therapy. The outcome measures of choice were American College of Rheumatology (ACR) 20/50/70 response rates.

Objective: To compare and find the best treatment for RA among Adalimumab (Drug A), Infliximab (Drug B) and Certolizumab (Drug C) by using three different methods of indirect treatment comparison (ITC) in meta-analysis.

Methods: Three different methods of ITC were used. They were—Bucher, a simplest method which compares two treatments through a single common comparator; Lumley, the network comparison which compares two treatments through more than one common comparator or linking treatment; and the Confidence Profile method which compares two treatments through many comparators by using Bayesian technique.

Results: The Odds ratio obtained from Bucher ITC was =0.417 (CI: 0.282 to 0.610) and =0.334 (CI: 0.226 to 0.495); Lumley’s OR was =0.327 (CI: 0.0041, 26) and =0.342 (CI: 0.0043, 27.15). By using Confidence Profile method, =0.369 (CI: 0.204, 0.76) and =0.305 (CI: 0.164, 0.636). The Odds ratio obtained from all the three methods was similar, concluding that Certolizumab is better as compared to Adalimumab and Infliximab.

 

Conclusion: Certolizumab is the best treatment for RA among various treatments.

 

Keywords: rheumatoid arthritis (RA), meta-analysis, indirect treatment comparison, Bayesian method, odds ratio

Cite this Article

Iswarya M. Indirect Treatment Comparison in Meta-Analysis Using Three Methods for Rheumatoid Arthritis. Research & Reviews: Journal of Computational Biology. 2018; 7(1): 22–27p.

Downloads

Published

2018-06-07

Issue

Vol. 7 No. 1 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.